Comparative Pharmacology
Head-to-head clinical analysis: MIUDELLA versus TRI NORINYL 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIUDELLA versus TRI NORINYL 28 DAY.
MIUDELLA vs TRI-NORINYL 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also increases viscosity of cervical mucus and alters endometrial lining to reduce implantation likelihood.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
One tablet orally once daily for 21 days, followed by one placebo tablet orally once daily for 7 days. Each active tablet contains 0.035 mg ethinyl estradiol and 0.5 mg norethindrone (7 days), 0.035 mg ethinyl estradiol and 1.0 mg norethindrone (9 days), and 0.035 mg ethinyl estradiol and 0.5 mg norethindrone (5 days).
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Ethinyl estradiol: 17 ± 6 hours (terminal); Norethindrone: 10 ± 3 hours (terminal). Steady-state achieved after 7-14 days.
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Renal: 40% as metabolites; Fecal: 50% as metabolites; Biliary: minor; unchanged ethinyl estradiol excreted in urine <5%, norethindrone <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive